Skip to content

Remimazolam for upper gastrointestinal endoscopy in high-risk patients: a non inferiority randomized controlled study

Remimazolam for upper gastrointestinal endoscopy in high-risk patients: a non inferiority randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066527
Enrollment
Unknown
Registered
2022-12-07
Start date
2022-12-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disease of upper digestive tract

Interventions

Sponsors

The Second People's Hospital of Futian District, Shenzhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Patients scheduled to undergo upper gastrointestinal endoscopy under programmed sedation; 3. ASA III and IV; 4. Patients who agreed to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse programmed sedation; 2. A history of drug abuse and/or alcoholism within the last 2 years; 3. Patients who have taken monoamine oxidase inhibitors or cytochrome P450 inhibitors within the last 1 month; 4. Patients with known allergy to benzodiazepines, opiates, propofol, lidocaine, or contraindications to the above drugs; 5. Patients who participated in clinical trials of other drugs within 3 months before the study began; 6. Pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frame
Composite endpoint indicator;

Countries

China

Contacts

Public ContactLi Zhi

The Second People's Hospital of Futian District, Shenzhen

lizhi0441@yeah.net+86 15112389212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026